RSS Feeds
Adriamycin Cardiotoxicity in Man
- JOHN J. RINEHART, M.D.;
- RICHARD P. LEWIS, M.D., F.A.C.P.; and
- STANLEY P. BALCERZAK, M.D., F.A.C.P.
Abstract
Noninvasive methods to detect early adriamycin-induced cardiac injury and to follow the course of the injury were prospectively studied. Serial physical examinations, chest X rays, electrocardiograms (ECG), and systolic time interval measurements were done. The pre-ejection period to left ventricular ejection time (PEP/LVET) ratio increased in eight of nine patients receiving a cumulative dose of 310 to 540 mg/m2 body surface area of adriamycin. Heart size increased in only two of these patients, and ECG changed in only one. PEP/LVET ratios improved 2 to 6 months after cessation of therapy. Persistently abnormal ratios improved in three of four patients after treatment with digoxin. Patients receiving a cumulative dose of 56 to 290 mg/m2 body surface area of adriamycin showed transient worsening of PEP/LVET ratios that returned to normal by 1 month after therapy. Patients receiving other chemotherapeutic agents had no increase in PEP/LVET ratios. Systolic time interval measurements are valuable in detecting early cardiotoxicity and in reducing the risk of life-threatening heart failure in patients receiving adriamycin.
Article and Author Information
-
▸From the Divisions of Hematology and Oncology, and Cardiology, Department of Medicine, Ohio State University College of Medicine, Columbus, Ohio.
-
Grant support: grants CA-04920-14 and CA-05192-06 from the National Institutes of Health, U.S. Public Health Service and grant CF 3032 from the American Cancer Society.
-
▸Requests for reprints should be addressed to Stanley P. Balcerzak, M.D., Ohio State University Hospital, 410 West 10th Ave., Columbus, OH 43210.
-
- Received March 11, 1974.
- Accepted June 13, 1974.
